MYLAN-ATORVASTATIN TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ATORVASTATIN (ATORVASTATIN CALCIUM)

Доступна с:

MYLAN PHARMACEUTICALS ULC

код АТС:

C10AA05

ИНН (Международная Имя):

ATORVASTATIN

дозировка:

10MG

Фармацевтическая форма:

TABLET

состав:

ATORVASTATIN (ATORVASTATIN CALCIUM) 10MG

Администрация маршрут:

ORAL

Штук в упаковке:

90/500

Тип рецепта:

Prescription

Терапевтические области:

HMG-COA REDUCTASE INHIBITORS

Обзор продуктов:

Active ingredient group (AIG) number: 0133055001; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2016-05-20

Характеристики продукта

_ _
_ _
_Page 1_
I
PRODUCT MONOGRAPH
PR
MYLAN-ATORVASTATIN
ATORVASTATIN CALCIUM TABLETS
10 MG, 20 MG, 40 MG AND 80 MG ATORVASTATIN
LIPID METABOLISM REGULATOR
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
DATE OF REVISION : MAY 3, 2016
SUBMISSION CONTROL NO.: 194039
_ _
_Page 2 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................
5
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
22
OVERDOSAGE
..........................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
24
STORAGE AND STABILITY
....................................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
.................................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 27
PART II: SCIENTIFIC INFORMATION
..................................................................................
28
PHARMACEUTICAL INFORMATION
.......................................